Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.
Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced that the multiple-ascending dose (MAD) Phase Ib clinical trial of HMS1005 (formerly known as HM-002-1005), a second-generation glucokinase activator (GKA) independently developed by the Company, has successfully completed the first patient dosing in the United States.
Recently, the Shanghai Municipal People's Government officially announced the winners of the Fifth Shanghai Intellectual Property Innovation Awards. Hua Medicine was honored with the Shanghai IPR Innovation Award (first prizes for patents) for its Chinese invention patent titled "Oral preparation of glucokinase activator and preparation method therefor". This recognition establishes the Company as a leading enterprise in intellectual property innovation within the biopharmaceutical industry.
ir@geersendoor.com
No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203
Privacy Statement Terms of Use
